Claims

1. Use of inhibitors of dipeptidylpeptidase IV (DP IV) as well as of inhibitors of enzymes having the same substrate specificity (DP IV-analogous enzyme activity) or/and of inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) respectively of inhibitors of enzymes having the same substrate specificity (APN-analogous enzyme activity) for the inhibition of the proliferation (DNA synthesis) of human sebaceous cells.

2. The use according to claim 1, wherein the inhibitors of DP IV are preferably Xaa-Pro-dipeptides (Xaa = α-amino acid or side-chain protected derivative), corresponding derivatives, preferably dipeptide phosphonic acid diaryl esters, dipeptide boronic acids (e. g. Pro-boro-Pro) and their salts, Xaa-Xaa-(Trp)-Pro-(Xaa)n peptides (Xaa = α-amino acid, n = 0 to 10), corresponding derivatives and their salts, amino acid (Xaa) amides, corresponding derivatives and their salts, wherein Xaa is an α-amino acid or a side chain-protected derivative, preferably N^{ε}-4-nitrobenzyl oxycarbonyl-L-lysine, L-isoleucine, L-valine, L-tryptophane, L-proline, and cyclic amines, for example, pyrrolidine, piperidine, thiazolidine and their derivatives act as the amide structure, tryptophane-1,2,3,4-tetrahydroisochinoline-3-carboxylic acid derivatives (TSL) and (2S,2S′,2S′′)-2-[2′-[2′′-amino-3′′-(indol-3′′′-yl)-1′′-oxoprolyl]-1′,2′, 3′,4′-tetrahydro-6′8′-dihydroxy-7-methoxyisochinol-3-yl-carbonyl-amino]-4-hydromethyl-5-hydropentanoic acid (TMC-2A).

3. The use according to claim 1, wherein amino acid amides, e.g. N^{ε}-4-nitrobenzyl-oxycarbonyl-L-lysine thiazolidide, -pyrrolidide and -piperidide as well as the corresponding 2-cyano thiazolidide, 2-cyano pyrrolidide and 2-cyano piperidide derivative are preferably used as DP IV inhibitors.

4. The use according to claim 1, wherein preferably actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, β-aminothiols, α-aminophosphinic acids, α-amino phosphinic acid derivatives, preferably D- Phe- ψ-[PO(OH)-CH_2]-Phe-Phe, and their salts act as inhibitors of APN.

5. Use of inhibitor combinations according to any of the claims 1 to 4 for the prevention and therapy of both benign follicular hyperproliferation conditions (acne, acneiform follicular reactions, steatocystoma multiplex, naevi of sebaceous glands, senile sebaceous gland hypertrophy, seborrhea of the skin and of the hair), SAHA syndrome [seborrhea, acne, hirsutism, alopecia] and malign follicular hyperproliferation conditions (mixed tumors, sebaceomes, naevus sebaceus with malign development, sebaceous gland tumors, sebaceous gland CA).

6. Pharmaceutical preparations, comprising inhibitors of dipeptidylpeptidase IV (DP IV) as well as of inhibitors of enzymes having a DP IV-analoguos enzyme activity or/and of inhibitors of alanyl aminopeptidase (aminopeptidase N, APN) as well as of inhibitors of enzymes having the same substrate specificity (APN-analogous enzyme activity) and in combination with per se known carrier substances, additives or/and auxiliary substances.

7. The pharmaceutical preparation according to claim 6, comprising as the inhibitors of the DP IV preferably Xaa-Pro-dipeptides (Xaa = α-amino acid or side-chain protected derivatives), corresponding derivatives, preferably dipeptide phosphonic acid diaryl esters and their salts, Xaa-Xaa-(Trp)-Pro-(Xaa)n peptides (Xaa = α-amino acid, n = 0 to 10), corresponding derivatives and their salts, amino acid (Xaa) amides, corresponding derivatives and their salts, wherein Xaa is an α-amino acid or a side chain-protected derivative, preferably N^{ϵ}-4-nitrobenzyl-oxycarbonyl-L-lysine, L-isoleucine, L-valine, L-tryptophane, L-proline, and cyclic amines, for example pyrrolidine, piperidine, thiazolidine and their derivatives act as the amide structure.

8. The pharmaceutical preparation according to claim 6, comprising as the inhibitors of the DP IV preferably amino acid amides, e.g. N^{ϵ}-4-nitrobenzyl-oxycarbonyl-L-lysine-thiazolidide, -pyrrolidide and -piperidide as well as the corresponding 2-cyano thiazolidide, 2-cyano pyrrolidide and 2-cyano piperidide derivative.

9. The pharmaceutical preparation according to claim 6, comprising as the inhibitors of the APN preferably actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, β-aminothiols, a-aminophosphinic acids, a-amino phosphinic acid derivatives, preferably D-Phe-ψ[PO(OH)-CH_2]-Phe-Phe, and their salts.

10. The pharmaceutical preparation according to any of claims 6 to 9, comprising two or more of the inhibitors of DP IV or inhibitors of enzymes having a DP IV-analogous enzyme activity or/and of the inhibitors of APN or inhibitors of enzymes having an APN-analogous enzyme activity, in a spaced-apart formulation in combination with per se known carrier substances, additives or/and auxiliary substances for a simultaneous or, with respect to time, immediately successive administration with the aim of a joint effect.

11. The pharmaceutical preparation according to any of claims 6 to 10 for a systemic administration for an oral, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal, sublingual application together with per se known carrier substances, additives or/and auxiliary substances.

12. The pharmaceutical preparation according to any of claims 6 to 10 for a topical administration in the form of cremes, ointments, pastes, gels, solutions, sprays, liposomes or nansomes, agitated mixtures, hydrocolloid dressings, and other dermatological bases/vehicles including instillative application.